Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
2016
Actavis Generics Allergan's generics business $40.5 billion |
| gptkbp:brand |
Recognized brand in pharmaceuticals
|
| gptkbp:businessModel |
Focus on both generics and specialty drugs
|
| gptkbp:CEO |
Kåre Schultz
|
| gptkbp:clinicalTrials |
Conducts numerous clinical trials annually
Invests in clinical research and trials |
| gptkbp:communityEngagement |
Supports various health initiatives
|
| gptkbp:communitySupport |
Supports local communities through donations
|
| gptkbp:corporateSocialResponsibility |
Engages in corporate social responsibility initiatives
|
| gptkbp:culturalHeritage |
Diversified product portfolio
|
| gptkbp:customerBase |
Serves a diverse customer base
|
| gptkbp:employees |
Approximately 40,000
Offers competitive employee benefits |
| gptkbp:financialPerformance |
Stock performance fluctuates
|
| gptkbp:financials |
Strives for financial stability
Faced financial challenges in recent years Publicly traded company with financial reports |
| gptkbp:founded |
1901
|
| gptkbp:globalPresence |
Operations in over 60 countries
|
| gptkbp:headCoach |
gptkb:Dr._Michael_Hayden
40,000 employees globally |
| gptkbp:headquarters |
gptkb:Parsippany-Troy_Hills,_New_Jersey
gptkb:Parsippany,_New_Jersey |
| https://www.w3.org/2000/01/rdf-schema#label |
Teva Pharmaceuticals USA
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Focus on innovative drug delivery systems
|
| gptkbp:investmentFocus |
Maintains investor relations department
|
| gptkbp:isMarketedAs |
One of the largest generic drug manufacturers
|
| gptkbp:legalStatus |
Involved in various legal disputes
|
| gptkbp:market |
$10 billion
Regularly launches new products Expanding into emerging markets Focus on high-demand therapeutic areas Leader in generic pharmaceuticals. |
| gptkbp:marketSegment |
Aggressive market strategy for generics
|
| gptkbp:parentCompany |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:partnerships |
Partnership with Pfizer
Collaborates with various healthcare organizations Partnership with Merck Partnership_with_Procter_&_Gamble |
| gptkbp:patentCitation |
Holds numerous patents for drugs
|
| gptkbp:products |
Specialty medicines
Ensures product safety and efficacy Generic_drugs |
| gptkbp:regulatoryCompliance |
Complies_with_FDA_regulations
|
| gptkbp:researchAndDevelopment |
Focus on oncology
Focus on neurological disorders Focus on respiratory diseases |
| gptkbp:revenue |
$16 billion
|
| gptkbp:stockSymbol |
gptkb:TEVA
|
| gptkbp:subsidiary |
gptkb:Teva_Canada
gptkb:Teva_Pharmaceuticals_Europe gptkb:Teva_UK Teva_API |
| gptkbp:supplyChain |
Global supply chain management
|
| gptkbp:sustainabilityInitiatives |
Focus on environmental sustainability
|
| gptkbp:training |
Invests in employee training programs
|
| gptkbp:website |
www.tevapharm.com
|